Loading
Alzheimer Disease / Disease Models, Animal / Alzheimer's Disease · Journal article
Experimental Neurology · July 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
Human astrocyte-derived extracellular vesicles from MCI and AD patients, when injected into aged PSAPP transgenic mice, induced motor coordination deficits and tau accumulation but did not alter amyloid plaque burden or astrogliosis at 6 months. The findings are exploratory and require replication to establish whether AEVs have utility as biomarkers or therapeutic targets in Alzheimer's disease.
Experimental animal study; uncontrolled injection of pooled human-derived extracellular vesicles into transgenic mice. Female PSAPP transgenic mice; human plasma from cognitively normal controls, MCI patients, and AD patients. Specific inclusion/exclusion criteria for human donors and mouse cohort allocation not detailed.. Intervention: Hippocampal injection of pooled astrocyte-derived extracellular vesicles isolated from MCI or AD patient plasma. Compared with: Astrocyte-derived extracellular vesicles isolated from cognitively normal control plasma.
Rotarod motor coordination showed significant impairment (p < 0.0001) in mice receiving MCI- and AD-AEVs versus CNC-AEVs Morris water maze trend toward faster escape latencies and increased target quadrant entries in CNC-AEVs mice did not reach statistical significance Increased cortical tau accumulation observed in MCI- and AD-AEV injected mice; Aβ/APP levels remained similar across all groups
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings are preclinical and exploratory. The detection of tau-related changes and motor deficits following AEV injection suggests a potential pathogenic role, but the lack of amyloid or glial changes and absence of cognitive deficits limit current clinical interpretation. Further validation is needed before considering AEVs as biomarkers or drug targets.
An uncontrolled mechanistic study in a transgenic mouse model using human-derived extracellular vesicles as a pooled intervention, with modest neuropathological changes and no primary clinical endpoint, requires confirmation before clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
These findings are preclinical and exploratory. The detection of tau-related changes and motor deficits following AEV injection suggests a potential pathogenic role, but the lack of amyloid or glial changes and absence of cognitive deficits limit current clinical interpretation. Further validation is needed before considering AEVs as biomarkers or drug targets.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Extracellular vesicles (EVs) are lipid-bound particles that transfer cargos between cells. While plasma neuronal-derived EVs (NEVs) from individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD) have been reported to exhibit high pathogenic potential, this study examined the impact of astrocyte-derived EVs (AEVs) in an aged AD mouse model. Plasma AEVs were isolated from cognitively normal control (CNC), MCI, and AD individuals using GLAST-based immunocapture and AEV size, purity, and tetraspanin were validated by flow cytometry, nanoparticle tracking, and super-resolution microscopy. AEVs pooled by clinical cohort were injected into the hippocampus of 6-month-old female PSAPP mice. Behavioral, biochemical, and neuropathological outcomes were assessed 6 months later. Rotarod assessment revealed significant impairment in motor coordination (p < 0.0001) in mice receiving MCI- and AD-AEVs compared with those receiving CNC-AEVs. While Morris water maze (MWM) also demonstrated that CNC-AEVs injected mice exhibited a trend toward increased target quadrant entries and faster escape latencies, these measures did not reach did not reach statistical significance. No overt changes were observed in the staining of amyloid plaque burden (6E10), and astrogliosis (GFAP). Immunoblotting of 82E1 and 22C11 confirmed Aβ/AAP levels remained similar across all injected mice, whereas increased cortical tau accumulation was observed in MCI- and AD-AEV injected mice. Cerebellar synaptic density (SY-38) remained unchanged. These findings suggest that while human-derived AEVs can precipitate early tau-related changes and motor coordination deficits, they do not significantly alter overall amyloidosis or astrocyte-reactivity at this time point. Further investigation is required to determine the viability of AEVs as biomarkers or therapeutic targets given the subtle nature of the observed structural pathology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.